Hypertension Diagnostics' Test Shown to Predict Hypertension Better Than Current Standards
April 20 2010 - 11:00AM
Marketwired
Hypertension Diagnostics, Inc. (OTCBB: HDII) (www.hdii.com) -- New
medical research data published in the American Journal of
Epidemiology provides significant evidence that Hypertension
Diagnostics, Inc.'s (HDI) non-invasive CardioVascular Profiling
test, which measures the elasticity of the small blood vessels, is
the earliest and best predictor of hypertension when compared to
several more established and expensive testing methodologies used
by physicians and cardiologists.
Hypertension affects almost 30% of the U.S. population and is
associated with a higher incidence of costly public health problems
such as stroke, cardiovascular disease, chronic kidney disease and
death. The data analyzed was from the Multi-Ethnic Study of
Atherosclerosis (MESA), a large study sponsored by the National
Heart, Lung, and Blood Institute (NHLBI) which included over 6,000
women and men of white, African American, Hispanic and Chinese
ethnicity, who are being followed over a 10-year period, are
between the ages of 45-84 years, and were free of cardiovascular
disease signs or symptoms.
The study participants were tested with four diagnostic
technologies: (1) coronary computed tomography -- sometimes
referred to as a CAT Scan or a Heart Scan -- which uses radioactive
x-rays to look for calcium deposits in the coronary arteries, (2)
carotid intimate media thickness test -- sometimes referred to as
Carotid IMT or carotid ultrasound -- which utilizes high frequency
ultrasound waves to image the arteries that supply blood to the
brain; (3) magnetic resonance imaging -- sometimes referred to as
MRI -- which utilizes a powerful magnetic field to visualize the
elasticity of the ascending aorta; and, (4) a non-invasive vascular
test using a research model of HDI's CVProfilor® which uses a safe
and simple sensor on the radial artery at the wrist to provide an
assessment of the elasticity of the small and large arteries
throughout the entire body.
When the results from these tests were evaluated relative to the
development of hypertension in the study population, HDI's small
artery elasticity index was shown to be the earliest predictor of
incident hypertension. These findings confirm that measurement of
small artery elasticity using HDI's CVProfilor can predict
hypertension.
"The results of this large trial are unmistakable and
potentially game-changing to the assessment of hypertension," said
Greg Guettler, president of HDI. "The data from this publication
indicates that the CVProfilor arterial elasticity test can identify
patients with hypertension better than and years earlier than more
expensive imaging technology that has been considered the standard
of care in patients at risk for cardiovascular disease. This study
illustrates both the need and the benefit that can be derived from
early cardiovascular disease detection."
"Given the recent published concerns about exposure to high
doses of radiation from Heart Scans, which may cause cataracts and
increase the risk for some forms of cancer, HDI's non-invasive
CardioVascular Profiling test does not use radiation," said Mark
Schwartz, chairman and CEO. "Because future health care legislation
will be focused on eliminating unnecessary and expensive tests in
favor of tests with strong predictive value and at a lower cost,
HDI's CVProfilor is well positioned to benefit from future health
care reform," said Schwartz.
About Hypertension Diagnostics, Inc.
Hypertension Diagnostics, Inc. ("HDI") manufactures and markets
medical devices for early detection and management of
cardiovascular disease in the U.S. and in 37 countries. Its main
product, the CVProfilor® DO-2020 CardioVascular Profiling System,
has been approved by the Food and Drug Administration (FDA), and is
being marketed to primary care physicians in the U.S. HDI's
CardioVascular Profiling Systems non-invasively measure both large
and small artery elasticity. Small artery elasticity has been shown
to be predictive of cardiovascular disease. Several large
pharmaceutical manufacturers have used HDI's CardioVascular
Profiling Systems in their multi-site clinical research trials.
There are over 300 published, peer-reviewed scientific articles and
presentations on HDI's methodology, which provides evidence on the
validity, accuracy and reproducibility of HDI's CardioVascular
Profiling technology. The technology was developed at the
University of Minnesota by a team led by world-renown cardiologist,
Dr. Jay N. Cohn.
Forward-looking statements in this press release are made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The Company wishes to caution readers not to
place undue reliance on any forward-looking statements and to
recognize that the statements are not a prediction of actual future
results. Actual results could differ materially from those
presented and anticipated in the forward-looking statements due to
the risks and uncertainties set forth in the Company's 2009 Annual
Report on Form 10-K, and subsequent Quarterly Reports on Form 10-Q,
all of which were filed with the U.S. Securities and Exchange
Commission, as well as others not now anticipated.
CVProfilor is a registered trademark of Hypertension
Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave,
PulseWave and CVProfile are trademarks of Hypertension Diagnostics,
Inc. All rights reserved. Website: www.hdii.com
Contact: Mark N. Schwartz, CEO (651) 687-9999
Hypertension Diagnositc (CE) (USOTC:HDII)
Historical Stock Chart
From Oct 2024 to Nov 2024
Hypertension Diagnositc (CE) (USOTC:HDII)
Historical Stock Chart
From Nov 2023 to Nov 2024